Skip to content
Peptides Codex
ENFR

Use the arrow keys to choose a result, Enter to open it, and Escape to close.

← Home
Signaling peptide (guanylin family)

Uroguanylin

Uroguanylin is a 16-amino-acid peptide secreted by enterochromaffin cells of the duodenum and encoded by GUCA2B.

By The Peptides Codex Editorial TeamIndividual review date not recorded

Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.

Length
16 aa
Class
Signaling peptide (guanylin family)
Function
Guanylate cyclase-C agonist; intestinal-renal salt-water and appetite signaling
Context
Gut-kidney axis and appetite physiology research

A 16-residue gut peptide linking intestinal salt handling to renal excretion and satiety.

Also known as: UGN · GUCA2B

Part of the Metabolic & GLP-1 peptides cluster

Overview

Uroguanylin is a 16-amino-acid peptide secreted by enterochromaffin cells of the duodenum and encoded by GUCA2B. As an endogenous guanylate cyclase-C agonist, it regulates intestinal and renal electrolyte and water transport and has been implicated in appetite and post-meal fullness. This page is educational and not medical advice.

Source & context

Biological / chemical source: Secreted by enterochromaffin cells of the small intestine (GUCA2B gene)

Primary research or clinical context: Gut-kidney axis and appetite physiology research

Gut-kidney signaling

Like guanylin, uroguanylin activates the guanylate cyclase-C receptor to raise cGMP and promote chloride and bicarbonate secretion. It is proposed to function as an intestinal natriuretic hormone, linking dietary salt intake to renal sodium excretion along a gut-kidney axis.

Metabolic interest

Beyond electrolyte handling, uroguanylin signaling has been associated with appetite regulation and sensations of fullness after meals. The GC-C agonist plecanatide is derived from uroguanylin, highlighting the therapeutic relevance of this endogenous peptide.

Structure & chemistry

Molecular identity & reference confidence

Source-supported reference

Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.

Molecular form
Uroguanylin (source record; form not independently established)
Species
Not established by this molecular identity audit
Termini (N / C)
Not specified / Not specified

Average reference mass

Reference policy updated: 2026-10-05

Molecular formula
C61H101N17O25S4
Average reference mass
≈ 1,600.8
Identifiers

Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.

Concentration math

Uroguanylin — reconstitution calculator

Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.

Reference form: Uroguanylin (source record; form not independently established)Average reference mass: 1,600.8 Da

Syringe graduation
Solution concentration
5 mg/mL5,000 mcg/mL
mcg

Enter an amount to see the volume it corresponds to.

Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.

Open the Uroguanylin calculator on its own page →

FAQ about Uroguanylin

What is Uroguanylin?+

Uroguanylin is a 16-amino-acid peptide secreted by enterochromaffin cells of the duodenum and encoded by GUCA2B. As an endogenous guanylate cyclase-C agonist, it regulates intestinal and renal electrolyte and water transport and has been implicated in appetite and post-meal fullness. This page is educational and not medical advice.

What Canadian product status is recorded for Uroguanylin?+

Canadian product status for Uroguanylin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.

What is the typical length of Uroguanylin?+

Uroguanylin is commonly described as approximately 16 amino acids (Signaling peptide (guanylin family)).

Related peptides

Guanylin
Signaling peptide (guanylin family)
Guanylin is a 15-amino-acid peptide secreted by goblet cells of the colon and encoded by GUCA2A. As an endogenous agonist of the guanylate cyclase-C (GC-C) receptor, it raises intracellular cGMP to regulate intestinal chloride, bicarbonate and water transport. This page is educational and not medical advice.
Phoenixin
Neuropeptide
Phoenixin (PNX) is a highly conserved neuropeptide first described in 2013 and processed from the SMIM20 prohormone into 14- and 20-residue forms. Signaling through the GPR173 receptor, it is studied for roles in reproduction, appetite, anxiety and energy metabolism. This page is educational and not medical advice.
Catestatin
Signaling peptide (chromogranin-derived)
Catestatin is a 21-amino-acid peptide cleaved from chromogranin A and released from neuroendocrine secretory granules. As a non-competitive nicotinic-cholinergic antagonist, it inhibits catecholamine (adrenaline/noradrenaline) release and is studied in blood-pressure regulation, metabolism and immunity. This page is educational and not medical advice.
BPC-157
Research pentadecapeptide (gastric-juice-derived sequence)
BPC-157 (Body Protection Compound-157) is a synthetic 15-residue peptide, GEPPPGKPADDAGLV, derived from a sequence found in human gastric juice. Hundreds of rodent studies, most from a single Zagreb group, report accelerated healing of tendon, muscle, ligament, gut and skin injuries via VEGFR2, nitric-oxide and ERK1/2 pathways. Human evidence is limited to a small safety study and a retrospective chart review; the first phase 2 efficacy trial began recruiting in 2026. It is not approved anywhere and the FDA barred it from compounding in 2023.

References & further reading

  1. 1.Yoshikawa et al. (2007). Haplotype-based case-control study of the association between the guanylate cyclase activator 2B (GUCA2B, Uroguanylin) gene and essential hypertension. Hypertens Res
  2. 2.Ikpa et al. (2016). Guanylin and uroguanylin are produced by mouse intestinal epithelial cells of columnar and secretory lineage. Histochem Cell Biol
  3. 3.Miner PB Jr et al. (2017). A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. Am J Gastroenterol
  4. 4.Frühbeck et al. (2022). High plasma and lingual uroguanylin as potential contributors to changes in food preference after sleeve gastrectomy. Metabolism
  5. 5.Zeng et al. (2022). Synergistic Effect of Uroguanylin and D(1) Dopamine Receptors on Sodium Excretion in Hypertension. J Am Heart Assoc
  6. 6.Fernández-Sáez et al. (2023). Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD. Metabolism
  7. 7.Brenna Ø et al. (2016). Cellular localization of guanylin and uroguanylin mRNAs in human and rat duodenal and colonic mucosa. Cell Tissue Res
  8. 8.Kim et al. (2016). Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity. Nutr Diabetes
  9. 9.Wikipedia — Uroguanylin
  10. 10.Wikipedia — Guanylate cyclase activator 2B (GUCA2B)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Uroguanylin educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.